The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Mirati Therapeutics, Inc(NASDAQ:MRTX) 
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NS...
Website: http://www.mirati.com
Founded: 1995
Full Time Employees: 111
Sector: Healthcare
Industry: Biotechnology
Mirati Therapeutics Days Payable Outstanding ttm (DPO)
Mirati Therapeutics Days Receivable Outstanding ttm (DSO)
Mirati Therapeutics Days Inventory Outstanding ttm (DIO)
Mirati Therapeutics Op Cashflow Per Share ttm
Mirati Therapeutics Free Cashflow Per Share ttm
Mirati Therapeutics Cash Per Share ttm
Mirati Therapeutics P/S ratio ttm
Mirati Therapeutics (GAAP) P/E ratio ttm
Mirati Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.